Cabaletta Bio heads into its June 9 earnings call with shorts adding sharply, borrow conditions loose, and a high-profile conference drop setting the clinical narrative for the week.
Short interest has risen fast and now commands serious attention. It has climbed 17% over the past week to 24.4% of the free float — roughly 23.5 million shares — the highest level recorded in the 30-day window tracked here. That is a significant acceleration: the position was closer to 19.5 million shares as recently as mid-May. The move pushed the ORTEX short score to 73.5, up from 67 a fortnight ago, placing CABA in the bottom 9th percentile by short score rank across the universe.
The lending market, however, does not yet reflect the squeeze conditions that such a large and fast-building position might suggest. Availability is running at 156% relative to estimated short interest — meaning there is roughly 1.6 shares available to borrow for every one already lent out. That is substantially looser than the 46–67% range that prevailed through most of April, when the borrow market was appreciably tighter. Cost to borrow has also eased, coming in below 0.7% — roughly a fifth of what it was a year ago and down almost 20% over the past month. New shorts face little friction entering the position at current levels.
The catalyst context matters here. Cabaletta presented new rese-cel data at the EULAR 2026 Congress this week, touting encouraging early findings in lupus and expanded support for its preconditioning-free approach. Separately, the company beat Q1 EPS estimates by $0.02 in mid-May, though the stock fell nearly 8% on the day, and earlier prints have been mixed: a 9% single-day drop in March after a data update, partially recovered over the subsequent five days, and a 2% gain last November that gave way to an 11% slide over the following week. The pattern is consistent — reaction to clinical events can be volatile, and the June 9 earnings call falls just days after the EULAR readout.
The Street remains broadly constructive but divided on conviction. Most buy-side names — Cantor Fitzgerald (Overweight, $30 target), Guggenheim (Buy, $16), and Citi (Buy, $10) — have maintained positive ratings, though targets differ widely. Wells Fargo, the lone Equal-Weight holder, raised its target from $2 to $4 in mid-May, a doubling that still sits well below the bull-camp consensus. With the mean analyst target near $14 against a current price of $3.68, the implied return potential is mathematically large — but that gap also reflects meaningful uncertainty about whether the CAART technology will prove out across its targeted autoimmune indications. The Cantor $30 target, unchanged since October, skews the average considerably and should be read in that light. Bears point to competitive pressure from other cell therapy platforms, patient and physician hesitancy around novel modalities in myositis and scleroderma, and COGS that remain challenging for autologous CAR-T at scale.
Institutional ownership shows a broadly supportive base. T. Rowe Price holds over 7% of shares. Millennium Management added more than 3 million shares in Q1, bringing its stake to 3.6% — one of the more decisive moves in the period. Cormorant Asset Management added 1.1 million shares to reach 3.4%. Against that backdrop, the building short position reflects a genuine debate: active managers adding on one side, systematic and opportunistic shorts adding on the other.
The June 9 call is the immediate focus. With shorts at a month-high and borrow still accessible, the market's reaction to management commentary on rese-cel's path to broader indications — and any update on the EULAR data reception — will determine whether the short-side pressure is validated or quickly unwinds.
See the live data behind this article on ORTEX.
Open CABA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
